A seemingly decisive Supreme Court ruling against gene patents in June left a lot of issues unsettled, and the industry can expect much more litigation to come, experts say.
The decision invalidated patents claimed by Myriad Genetics against rival Ambry Genetics on the use of naturally occurring DNA sequences in tests for the risk of breast cancer. Yet on July 9, Myriad filed another lawsuit against Ambry and Gene by Gene, citing other patent violations
The Myriad case marks the beginning of a cultural shift in how biotech patents are viewed, to take into account public needs, said University of Michigan researcher Shobita Parthasarathy. But other decisions, and a change of attitude from the U.S. Patent and Trademark Office, will be needed to confirm that shift.
Share this article
Read the full, original story here: Gene patent ruling leaves unanswered questions
